In a major milestone for mental health care, Austin-based Choose Your Horizon Inc., also known as Choose Ketamine, has announced the completion of its seed financing round. Led by Manifestations Capital in collaboration with Notley Ventures and numerous industry veterans and thought leaders, this
Read More
The well-known psychedelic biotech company Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) announced that it has been granted a Pre-Investigational New Drug (Pre-IND) meeting by the U.S. Food and Drug Administration (FDA) for new chemical entity Triptax™. Biomind Labs is devoted to crafting innovative pharmaceuticals for patients with neurological and psychiatric disorders, using
Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced today that
Numinus Wellness Inc.’s (OTCQX: NUMIF) (TSX: NUMI) research division, Numinus Bioscience, recently
The first part in the new MAPS Digital Learning initiative is Psychedelic Fundamentals, which introduces those interested in learning to the fundamental
Zylorion announced today the filing of the Company’s third provisional patent application with the United States Patent and Trademark Office (“USPTO”). The
The nation’s largest ketamine therapy provider now offers complimentary patient resources supporting holistic mental health treatment. On Thursday, the largest ketamine therapy
Clinical-stage biotechnology Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) has strengthened their intellectual property portfolio with a new provisional patent designed to treat
